Jubilant Therapeutics Inc. to Present Data on Isoform Selective PAD4 inhibitors in the Treatment of Cancer at the American Association of Cancer Research Annual (AACR) Meeting 2022
BEDMINSTER, N.J., March 10, 2022 /PRNewswire/ -- Jubilant Therapeutics Inc. ('Jubilant'), a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical
United States Luca Rastelli Kostenloser Wertpapierhandel Dhanalakshmi Sivanandhan Prnewswire Jubilant Therapeutics Inc American Association Of Cancer Research Annual
Source: finanznachrichten.de